https://stock.noler.com/us/stock/simcere-pharmaceutical-group https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accounts-notes-and-loans-receivable-net-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accounts-payable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accounts-receivable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accounts-receivable-gross-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accounts-receivable-related-parties-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accrued-income-taxes-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accrued-marketing-costs-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accrued-professional-fees-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/accumulated-depreciation https://stock.noler.com/us/stock/simcere-pharmaceutical-group/acquisitions https://stock.noler.com/us/stock/simcere-pharmaceutical-group/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/simcere-pharmaceutical-group/advances-to-affiliate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/advertising-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/allowance-for-doubtful-accounts-receivable-charge-offs https://stock.noler.com/us/stock/simcere-pharmaceutical-group/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/allowance-for-notes-and-loans-receivable-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/amortization https://stock.noler.com/us/stock/simcere-pharmaceutical-group/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/simcere-pharmaceutical-group/aoci https://stock.noler.com/us/stock/simcere-pharmaceutical-group/asset-impairment-charges https://stock.noler.com/us/stock/simcere-pharmaceutical-group/assets-held-for-sale-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/basic-shares https://stock.noler.com/us/stock/simcere-pharmaceutical-group/buybacks-share-repurchases https://stock.noler.com/us/stock/simcere-pharmaceutical-group/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/simcere-pharmaceutical-group/capital-expenditures https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cash https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cash-and-equivalents https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cash-change https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cash-flow-breakdown https://stock.noler.com/us/stock/simcere-pharmaceutical-group/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/simcere-pharmaceutical-group/common-stock-value https://stock.noler.com/us/stock/simcere-pharmaceutical-group/comprehensive-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/comprehensive-income-net-of-tax-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cost-of-goods-sold https://stock.noler.com/us/stock/simcere-pharmaceutical-group/cover-page-shares-outstanding https://stock.noler.com/us/stock/simcere-pharmaceutical-group/current-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/current-income-tax-expense-benefit https://stock.noler.com/us/stock/simcere-pharmaceutical-group/current-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/customer-advances-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-income-tax-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-gross https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-inventory https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-liabilities-net-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-net https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-accrued-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-allowance-for-doubtful-accounts https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-liabilities-investment-in-noncontrolled-affiliates https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deferred-tax-liabilities-property-plant-and-equipment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deposit-liability-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/deposits-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/depreciation https://stock.noler.com/us/stock/simcere-pharmaceutical-group/diluted-shares https://stock.noler.com/us/stock/simcere-pharmaceutical-group/due-from-related-parties https://stock.noler.com/us/stock/simcere-pharmaceutical-group/due-from-related-parties-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/due-from-related-parties-noncurrent https://stock.noler.com/us/stock/simcere-pharmaceutical-group/due-to-related-parties-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/due-to-related-parties-current-and-noncurrent https://stock.noler.com/us/stock/simcere-pharmaceutical-group/effect-of-exchange-rate-on-cash-and-cash-equivalents https://stock.noler.com/us/stock/simcere-pharmaceutical-group/employee-related-liabilities-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/eps https://stock.noler.com/us/stock/simcere-pharmaceutical-group/eps-basic https://stock.noler.com/us/stock/simcere-pharmaceutical-group/equity-method-investment-other-than-temporary-impairment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/simcere-pharmaceutical-group/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/simcere-pharmaceutical-group/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/simcere-pharmaceutical-group/foreign-currency-transaction-gain-loss-unrealized https://stock.noler.com/us/stock/simcere-pharmaceutical-group/gain-loss-on-sale-of-notes-receivable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/gain-or-loss-on-sale-of-stock-in-subsidiary https://stock.noler.com/us/stock/simcere-pharmaceutical-group/general-and-administrative-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/goodwill https://stock.noler.com/us/stock/simcere-pharmaceutical-group/goodwill-gross https://stock.noler.com/us/stock/simcere-pharmaceutical-group/goodwill-impaired-accumulated-impairment-loss https://stock.noler.com/us/stock/simcere-pharmaceutical-group/goodwill-impairment-loss https://stock.noler.com/us/stock/simcere-pharmaceutical-group/gross-profit https://stock.noler.com/us/stock/simcere-pharmaceutical-group/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/simcere-pharmaceutical-group/impairment-of-long-lived-assets-held-for-use https://stock.noler.com/us/stock/simcere-pharmaceutical-group/income-loss-from-equity-method-investments https://stock.noler.com/us/stock/simcere-pharmaceutical-group/income-tax https://stock.noler.com/us/stock/simcere-pharmaceutical-group/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/income-tax-holiday-aggregate-dollar-amount https://stock.noler.com/us/stock/simcere-pharmaceutical-group/income-taxes-paid https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-accounts-and-other-receivables https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-accounts-payable-trade https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-due-from-related-parties-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-inventories https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-other-current-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-other-current-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/increase-decrease-in-other-operating-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/incremental-common-shares-attributable-to-share-based-payment-arrangements https://stock.noler.com/us/stock/simcere-pharmaceutical-group/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/simcere-pharmaceutical-group/interest-costs-incurred https://stock.noler.com/us/stock/simcere-pharmaceutical-group/interest-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/interest-paid-net https://stock.noler.com/us/stock/simcere-pharmaceutical-group/inventory https://stock.noler.com/us/stock/simcere-pharmaceutical-group/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/simcere-pharmaceutical-group/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/simcere-pharmaceutical-group/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/simcere-pharmaceutical-group/inventory-write-down https://stock.noler.com/us/stock/simcere-pharmaceutical-group/investment-income-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/investments-in-affiliates-subsidiaries-associates-and-joint-ventures https://stock.noler.com/us/stock/simcere-pharmaceutical-group/investments-in-and-advances-to-affiliates-dividends-or-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/loans-payable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/long-term-loans-payable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/minority-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/minority-interest-decrease-from-distributions-to-noncontrolling-interest-holders https://stock.noler.com/us/stock/simcere-pharmaceutical-group/minority-interest-decrease-from-redemptions https://stock.noler.com/us/stock/simcere-pharmaceutical-group/minority-interest-in-net-income-loss-other-minority-interests https://stock.noler.com/us/stock/simcere-pharmaceutical-group/minority-interest-increase-from-stock-issuance https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-cash-from https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-cash-from-financing-activities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-cash-from-investing-activities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-cash-from-operating-activities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-income-loss-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/net-income-loss-attributable-to-redeemable-noncontrolling-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/noncash-or-part-noncash-acquisition-payables-assumed https://stock.noler.com/us/stock/simcere-pharmaceutical-group/noncontrolling-interest-increase-from-business-combination https://stock.noler.com/us/stock/simcere-pharmaceutical-group/notes-and-loans-receivable-net-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/simcere-pharmaceutical-group/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/simcere-pharmaceutical-group/operating-leases-rent-expense-net https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-accrued-liabilities-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-current-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-current-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-noncurrent-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-noncurrent-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-nonoperating-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/other-operating-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-for-advance-to-affiliate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-of-dividends-minority-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-to-acquire-businesses-and-interest-in-affiliates https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-to-acquire-intangible-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-to-fund-longterm-loans-to-related-parties https://stock.noler.com/us/stock/simcere-pharmaceutical-group/payments-to-minority-shareholders https://stock.noler.com/us/stock/simcere-pharmaceutical-group/pretax-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-collection-of-advance-to-affiliate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-issuance-of-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-minority-shareholders https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-other-equity https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-related-party-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-repayments-of-related-party-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-sale-of-notes-receivable https://stock.noler.com/us/stock/simcere-pharmaceutical-group/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/profit-loss https://stock.noler.com/us/stock/simcere-pharmaceutical-group/property-plant-and-equipment-gross https://stock.noler.com/us/stock/simcere-pharmaceutical-group/property-plant-equipment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/provision-for-doubtful-accounts https://stock.noler.com/us/stock/simcere-pharmaceutical-group/redeemable-noncontrolling-interest-equity-common-carrying-amount https://stock.noler.com/us/stock/simcere-pharmaceutical-group/repayments-of-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/repayments-of-related-party-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/research-and-development https://stock.noler.com/us/stock/simcere-pharmaceutical-group/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/simcere-pharmaceutical-group/retail-related-inventory-packaging-and-other-supplies https://stock.noler.com/us/stock/simcere-pharmaceutical-group/retained-earnings https://stock.noler.com/us/stock/simcere-pharmaceutical-group/revenue-from-grants https://stock.noler.com/us/stock/simcere-pharmaceutical-group/revenue-from-related-parties https://stock.noler.com/us/stock/simcere-pharmaceutical-group/sales-and-excise-tax-payable-current https://stock.noler.com/us/stock/simcere-pharmaceutical-group/sales-revenue-goods-net https://stock.noler.com/us/stock/simcere-pharmaceutical-group/selling-and-marketing-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/shareholders-equity https://stock.noler.com/us/stock/simcere-pharmaceutical-group/shares-authorized https://stock.noler.com/us/stock/simcere-pharmaceutical-group/shares-issued https://stock.noler.com/us/stock/simcere-pharmaceutical-group/shipping-handling-and-transportation-costs https://stock.noler.com/us/stock/simcere-pharmaceutical-group/short-term-debt https://stock.noler.com/us/stock/simcere-pharmaceutical-group/short-term-debt-weighted-average-interest-rate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/significant-change-in-utb-is-reasonably-possible-amount-of-unrecorded-benefit https://stock.noler.com/us/stock/simcere-pharmaceutical-group/stock-based-compensation https://stock.noler.com/us/stock/simcere-pharmaceutical-group/stock-issued-shares-issued-value-share-based-compensation-gross https://stock.noler.com/us/stock/simcere-pharmaceutical-group/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/simcere-pharmaceutical-group/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-nondeductible-expense-impairment-losses https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-nondeductible-expense-meals-and-entertainment https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-tax-exempt-income https://stock.noler.com/us/stock/simcere-pharmaceutical-group/tax-reconciliation-tax-holidays https://stock.noler.com/us/stock/simcere-pharmaceutical-group/total-assets https://stock.noler.com/us/stock/simcere-pharmaceutical-group/total-liabilities https://stock.noler.com/us/stock/simcere-pharmaceutical-group/total-liabilities-and-equity https://stock.noler.com/us/stock/simcere-pharmaceutical-group/unrecognized-tax-benefits https://stock.noler.com/us/stock/simcere-pharmaceutical-group/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/simcere-pharmaceutical-group/utb-interest-on-income-taxes-expense https://stock.noler.com/us/stock/simcere-pharmaceutical-group/utb-that-would-impact-effective-tax-rate https://stock.noler.com/us/stock/simcere-pharmaceutical-group/valuation-allowance-deferred-tax-asset-change-in-amount